Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Retroviral risk

Jonathan B Weitzman

Genome Biology 2002, 3:spotlight-20020423-01  doi:10.1186/gb-spotlight-20020423-01

The electronic version of this article is the complete one and can be found online at:


Published:23 April 2002

© 2002 BioMed Central Ltd

Research news

Gene therapy strategies have been riddled with technical problems and much-publicized risks. In the April 19 Science, Li et al. deal another blow to gene therapy (Science 2002, 296:497). They found that when they used replication-defective retroviruses to deliver a marker gene to mouse bone marrow cells, the animals developed leukemia. Li et al. transplanted the bone marrow cells into irradiated recipients; all these animals developed hematopoietic disorders after six months. All the diseased mice had the same leukemic clone with a single integrated vector copy. The insertion event induced expression of the Evi1 gene, encoding a transcription factor linked to acute myeloid leukemia. The authors suggest that the marker transgene may also contribute to tumor formation. The risk of cancer is yet another factor that must be considered in future gene therapy trials.

References

  1. [http://www.sciencemag.org] webcite

    Science

  2. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells.

    PubMed Abstract | Publisher Full Text OpenURL